Viridian Therapeutics, Inc. VRDN Veligrotug — Purchase commitment
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermPurchaseCommitmentAmount.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
Under the WuXi Commercial Supply Agreement, each month the Company is required to provide WuXi with a rolling forecast schedule detailing batch volume requirements for veligrotug drug substance and drug product. The volume requirements are binding for a period of twelve months with respect to drug substance and nine months with respect to drug product. In addition to service fees, the Company is required to pay variable pass-through costs based on costs incurred by WuXi to procure materials in connection with the manufacturing services. As of June 30, 2026, the Company had outstanding non-cancelable purchase commitments of approximately $14.1 million under the agreement.
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s veligrotug — purchase commitment?
- Viridian Therapeutics, Inc. (VRDN) reported veligrotug — purchase commitment of $14.1M in Q2 2026.
- What does veligrotug — purchase commitment mean?
- This metric represents the total aggregate financial obligation or volume requirement committed to for the procurement of Veligrotug. It serves as a key indicator of the company's anticipated manufacturing or supply needs for this specific product candidate. Monitoring this commitment helps investors gauge the scale of commercialization preparation and potential future cash outflows.
Ask your AI about Viridian Therapeutics, Inc.'s veligrotug — purchase commitment.
Connect your AI assistant and compare it to peers, right in your chat.
